- CARTITUDE-4 study shows 80% of standard-risk myeloma patients remain treatment-free at 2.5 years after CARVYKTI® infusion.
- 176 patients received CARVYKTI® as early as second line, with 59 having standard-risk cytogenetics.
- At 33.6 months follow-up, 30-month progression-free survival rate plateaued at 80.5% for standard-risk patients.
- Translational analysis links stronger immune fitness to longer progression-free survival in early treatment lines.
Study Overview
The Phase 3 CARTITUDE-4 study highlights the efficacy of CARVYKTI® (ciltacabtagene autoleucel) in treating relapsed or refractory multiple myeloma (RRMM). The study shows that 80% of standard-risk patients remained progression-free and did not require further treatment 2.5 years after a single infusion.
Patient Data
In the study, 176 patients received CARVYKTI® as early as the second line of treatment, with 59 of these patients having standard-risk cytogenetics. At a median follow-up of 33.6 months, the 30-month progression-free survival (PFS) rate for standard-risk patients plateaued at 80.5%.
Immune Fitness and Survival
Translational analyses suggest that patients treated with CARVYKTI® in earlier lines of therapy exhibit improved immune fitness, which correlates with longer PFS. This is characterized by increased baseline CD4⁺ naïve T cells in peripheral blood and a more immune-activated profile in bone marrow tumor analyses.
Implications for Treatment
The findings indicate that using CARVYKTI® after one or two prior lines of therapy may enhance survival outcomes, supporting its use in earlier treatment stages for RRMM patients. The study emphasizes the potential for achieving deeper and more durable responses, shifting the treatment paradigm towards long-term remission.
